TrialJournal for immunotherapy of cancer2026

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Emily K Ninmer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.